Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 12/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2893322 | 0.88 | MPO (0.35) | FAAHMGLLMPOGRM5KEAP1 | |
| SCHEMBL2892918 | 0.83 | GRM5 (0.34) | FAAHMGLLMPOGRM5 | |
| SCHEMBL2896574 | 0.76 | HPGD (0.43) | FAAHMGLLMPOGRM5KEAP1 | |
| SCHEMBL2894869 | 0.75 | GRM5 (0.39) | FAAHMGLLMPOGRM5 | |
| SCHEMBL2894710 | 0.74 | GRM5 (0.39) | FAAHMGLLMPOGRM5KEAP1 | |
| SCHEMBL2910592 | 0.73 | HPGD (0.40) | FAAHMGLLMPOGRM5KEAP1 | |
| SCHEMBL2893751 | 0.72 | FAAH (0.40) | FAAHMGLLMPOGRM5KEAP1 | |
| SCHEMBL2001185 | 0.71 | GRM5 (0.46) | MGLLGRM5 | |
| SCHEMBL3115514 | 0.71 | GRM5 (0.46) | MGLLGRM5 | |
| SCHEMBL2002209 | 0.71 | GRM5 (0.46) | MGLLGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691892-B2 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| US-20070197549-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
| EP-1716125-A1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060004021-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| WO-2005080356-A1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004021-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM4 | FAAH 1900/4885MGLL 3508/4885MPO 2407/4885 |
| US-20070197549-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM4 | FAAH 1858/4885MGLL 3471/4885MPO 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.